SCHEMBL7141656

SCHEMBL7141656

CNCC(=O)N(C)c1ccccc1C(=O)OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.54
KDM4E B2RXH2 4/20 0.46
POLB P06746 2/20 0.46
ATM Q13315 1/20 0.46
LMNA P02545 2/20 0.45
TSHR P16473 1/20 0.45
ALDH1A1 P00352 4/20 0.44
HSD17B10 Q99714 3/20 0.44
CFTR P13569 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.42
GLA P06280 1/20 0.41
GAA P10253 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HPGD P15428 1/20 0.40
MEN1 O00255 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA5A P35218 1/20 0.40
CA9 Q16790 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7141659 0.98 KMT2A (0.52) KMT2AKDM4EPOLBATMLMNA
SCHEMBL13041521 0.84 KMT2A (0.56) KMT2AKDM4EPOLBATMLMNA
SCHEMBL7819216 0.83 KMT2A (0.55) KMT2AKDM4EPOLBATMLMNA
SCHEMBL2635516 0.83 KMT2A (0.55) KMT2AKDM4EPOLBATMLMNA
SCHEMBL29981090 0.83 KMT2A (0.55) KMT2AKDM4EPOLBATMLMNA
SCHEMBL9369081 0.82 KMT2A (0.54) KMT2AKDM4EPOLBATMLMNA
SCHEMBL13041484 0.81 KMT2A (0.52) KMT2AKDM4EPOLBATMLMNA
SCHEMBL17702649 0.79 KMT2A (0.51) KMT2AKDM4EPOLBATMLMNA
SCHEMBL28409026 0.79 KMT2A (0.61) KMT2AKDM4EPOLBATMLMNA
SCHEMBL26525031 0.78 TRPM8 (0.43) KMT2AKDM4ELMNATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP KMT2A 1971/4885KDM4E 1295/4885POLB 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.